ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer

PURPOSE: We evaluated the clinical utility of excision repair cross-complementation group 1 (ERCC1) expression as a predictive biomarker for platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Eligible patients were randomly assigned to the GP (gemcitab...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ji-Youn, Lee, Geon Kook, Lim, Kun Young, Lee, Young Ju, Nam, Byung Ho, Lee, Jin Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512356/
https://www.ncbi.nlm.nih.gov/pubmed/27737534
http://dx.doi.org/10.4143/crt.2016.365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512356/
https://www.ncbi.nlm.nih.gov/pubmed/27737534
http://dx.doi.org/10.4143/crt.2016.365

Ejemplares similares